Introduction
Addressing an Unmet Need
Product Info
Pharmacological class
Clinical Studies
Menopausal Symptoms
FemarelleŽ & Bone Loss
    . Effect on Bone Mineral Density
    . Mechanism of action in the bone
    . Skeletal tissue & the uterus
    . Histology of skeletal tissue
FemarelleŽ & Breast Tissue
FemarelleŽ as a SERM
FAQ
Manufacturing Procedure

   
Scientific Overview

The clinical and pre-clinical evidence presented in this site show that Femarelle® acts as a novel Selective Estrogen Receptor Modulator (SERM) that affects estrogen receptors only in specific sites, without affecting tissues where any change can have dangerous consequences.

Femarelle® taken twice a day is effective in relieving menopausal symptoms and increasing bone mineral density (BMD). Clinical research and experience have shown that relief of menopausal symptoms is felt, on average, within the first week of treatment. Three in four women report relief, with alleviation of hot flushes in 76%, relief of joint and muscle pain in 70%, and relief of headaches in 68% (the main symptoms associated with the menopause transition). These rates were statistically significant (P <0.01).

The effect of Femarelle® on bone showed a statistically significant increase of 2.0% of BMD in the hip and of 3.6% in the spine after 12 months of treatment. The positive effect of Femarelle® on bones was also demonstrated in animal models.

These clinical results were achieved without causing changes in the hormonal blood profile and without leading to any change in endometrial thickness or other changes in the uterus.

A study of its mechanism of action on BMD in human bone cultures showed that Femarelle® exhibits unique bone-forming properties by increasing bone formation through osteoblast activity, thus inducing bone rejuvenation.

In a human breast cancer tissue culture study, Femarelle® had no effect on breast cancer tissue.

The unique combination of coumestans and lignans in Femarelle® represents a novel and effective treatment. There are no other chemically similar treatments for human use. The selective mechanism of action of Femarelle® allows it to act as an agonist on the estrogen receptors and thus to exert a favorable effect on menopausal symptoms and the BMD, while having an antagonistic effect on the estrogen receptors in breast tissue and in the uterus.

Femarelle® is constantly being studied; the results are presented in leading medical conferences around the world and published in scientific and medical journals. We will keep you up to date on all the developments and new publications in this website.

 
Home   Site Map   Disclamer © Se-cure Pharmaceuticals Ltd.